Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith S Currier

Showing results (281-290 of 298) with videos related to

Pageof 30
Sort By:
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 6, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE TrialLiying Xue, Romit Bhattacharya, Md Mesbah Uddin, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
The New England Journal of Medicine|November 3, 2016
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV PreventionMary G Fowler, Min Qin, Susan A Fiscus, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
The Journal of Infectious Diseases|July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE TrialTomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2023
Early Treatment, Inflammation and Post-COVID ConditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Mbio|September 19, 2023
Early antibody treatment, inflammation, and risk of post-COVID conditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Pageof 30

Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 6, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE TrialLiying Xue, Romit Bhattacharya, Md Mesbah Uddin, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
The New England Journal of Medicine|November 3, 2016
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV PreventionMary G Fowler, Min Qin, Susan A Fiscus, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
The Journal of Infectious Diseases|July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE TrialTomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2023
Early Treatment, Inflammation and Post-COVID ConditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Mbio|September 19, 2023
Early antibody treatment, inflammation, and risk of post-COVID conditionsKelly A Gebo, Sonya L Heath, Yuriko Fukuta, et al.
Pageof 30